The European Commission has announced that it will review the EU Medical Devices Regulation (MDR) again and make targeted adjustments.
The background to this is feedback from the market that certain requirements of the MDR in their current form lead to high administrative and economic burdens.
The MDR (Regulation (EU) 2017/745) came into force as the successor to the previous Medical Devices Directive (MDD) in order to strengthen harmonisation in the European market, increase patient protection and further raise the quality and safety standards for medical devices.
Key changes concerned in particular conformity assessment, technical documentation requirements and Post-Market-Surveillance .
Many of these regulations were deliberately introduced in stages. For example, mandatory product registration via EUDAMED is not expected to apply fully to all products until 2027/2028.
The planned changes focus in particular on:
However, even before all transitional arrangements have expired, the European Commission now sees a need for adjustment. In its own assessment, individual MDR requirements lead to high costs, longer development cycles and, in certain areas, supply bottlenecks. Against this backdrop, the Commission announced in December 2025 that it would initiate a targeted revision of the MDR.
- Simplifications in approval and conformity procedures
- A reduction in administrative burdens for manufacturers
- Relief for notified bodies
- A better balance between regulatory certainty and market access
For many manufacturers, these adjustments could mean relief in the medium term. At the same time, transitional scenarios are emerging in which companies are affected by the changes to varying degrees, depending on the status of their MDR implementation and internal processes.
From a regulatory perspective, one key challenge remains: the MDR must be further developed in such a way that the European market remains innovative and competitive without compromising the high quality and safety standards for which European medical devices are internationally renowned.
Exactly what the future shape of the MDR will look like is still unclear at present. However, one thing is certain: manufacturers should closely monitor regulatory developments and review their strategies at an early stage in order to remain capable of acting – regardless of the final outcome of the reform.
BEO BERLIN continuously monitors developments relating to MDR 2.0, classifies them according to technical criteria and supports manufacturers in the safe and pragmatic implementation of regulatory requirements – in the EU, the UK, the USA and Canada.
Contact us for ongoing advice on regulatory affairs or arrange a free initial consultation with our experts.
(2 Rating(s), average: 5.00 out of 5)
Loading...
